Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Key facts
- Who runs it
- Brown University
- Where
- Burlington and Providence, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 326 people enrolled
- Started
- 18 Oct 2020
- Ended
- 27 Nov 2023
- Type of study
- Interventional, 4 groups
- Treatments tested
- Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
- E-Cigarettes
- Record updated
- 1 April 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Between 21 years and 70 years old
- Must have current diagnosis of an Affective Disorder
Who cannot take part
- Being without an Affective Disorder
- Younger than 21 years old
- Older than 70 years old
Where in United States
- University of VermontBurlington, United States
- Brown UniversityProvidence, United States
About the trial
What the trial wants to find out
While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions. Affective Disorders (ADs) are the most common mental health conditions in the US, and over 40% of people with ADs are current smokers. A national policy of reducing the nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse consequences.
Read full original descriptionShow less
The goal of the proposed trial is to experimentally model whether increasing the availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the effect of altering the nicotine in cigarettes in smokers with ADs. Additionally, investigators will test whether allowing participants to personalize the flavor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking.
Daily smokers with current ADs will be recruited at Brown University and the University of Vermont.
Investigators will study two research cigarettes referred to here as Research Cigarette 1 (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine content cigarette and the other will be a reduced nicotine content cigarette. Investigators will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially available devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be available only in tobacco flavor while in the other condition that e-liquid will be available in multiple flavors from which participants can choose based on personal taste preference. Participants will be assigned to one of the following four study conditions: (1) RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.
Participants will be asked to use only their assigned study products for 16 weeks. Outcome measures include total CPD, cigarette demand assessed by behavioral economics-based purchase tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional nitric oxide concentration in exhaled breath [FeNO]).
The 4 groups in the trial
- RC 1 onlyTreatment being tested
Research Cigarettes #1
Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
- RC 2 onlyTreatment being tested
Research Cigarettes #2
Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
- RC 2 + EC 1Treatment being tested
Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)
Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) and E-Cigarettes
- RC 2 + EC 2Treatment being tested
Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)
Treatment: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) and E-Cigarettes
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A further examination of the validity of assessing demand intensity using the Cigarette Purchase Task.Experimental and clinical psychopharmacology, 2026
- Reduced Nicotine Cigarettes and E-Cigarettes in High-Risk Populations: 3 Randomized Clinical Trials.JAMA network open, 2024
- Record updated
- 1 April 2025